<?xml version='1.0' encoding='utf-8'?>
<document id="17535786"><sentence text="[Number and nature of drug interactions concerning antineoplastic drugs]." /><sentence text="Antineoplastic drugs are prone to drug-drug interactions" /><sentence text=" Cancer patients often receive multiple concurrent medications and health care professionals are not always aware that patients are also taking others treatments" /><sentence text=" The aim of this study was to assess the number of drug-drug interactions of antineoplastic drugs used in solid tumours and to find out and collect recommendations for each of them" /><sentence text=" We performed a bibliographic search from the Vidal dictionary, the &quot;thesaurus de l'Afssaps&quot;, the &quot;dossier du CNHIM&quot; and from literature of scientific journals" /><sentence text=" For the 40 antineoplastic drugs studied, 726 drug-drug interactions were identified; 186 from the Vidal dictionary, 356 from scientific literature and 184 from others bibliographic sources" /><sentence text=" The most frequently involved antineoplastic drugs are ifosfamide, paclitaxel and erlotinib"><entity charOffset="55-65" id="DDI-PubMed.17535786.s7.e0" text="ifosfamide" /><entity charOffset="67-77" id="DDI-PubMed.17535786.s7.e1" text="paclitaxel" /><entity charOffset="82-91" id="DDI-PubMed.17535786.s7.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.17535786.s7.e0" e2="DDI-PubMed.17535786.s7.e0" /><pair ddi="false" e1="DDI-PubMed.17535786.s7.e0" e2="DDI-PubMed.17535786.s7.e1" /><pair ddi="false" e1="DDI-PubMed.17535786.s7.e0" e2="DDI-PubMed.17535786.s7.e2" /><pair ddi="false" e1="DDI-PubMed.17535786.s7.e1" e2="DDI-PubMed.17535786.s7.e1" /><pair ddi="false" e1="DDI-PubMed.17535786.s7.e1" e2="DDI-PubMed.17535786.s7.e2" /></sentence><sentence text=" The ATC groups of associated drugs are antiinfectives for systemic use, alimentary tract and metabolism and nervous system" /><sentence text=" Antiretrovirals are prone to drug interactions with antineoplastic drugs, particularly ritonavir, tipranavir and efavirenz"><entity charOffset="88-97" id="DDI-PubMed.17535786.s9.e0" text="ritonavir" /><entity charOffset="99-109" id="DDI-PubMed.17535786.s9.e1" text="tipranavir" /><entity charOffset="114-123" id="DDI-PubMed.17535786.s9.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.17535786.s9.e0" e2="DDI-PubMed.17535786.s9.e0" /><pair ddi="false" e1="DDI-PubMed.17535786.s9.e0" e2="DDI-PubMed.17535786.s9.e1" /><pair ddi="false" e1="DDI-PubMed.17535786.s9.e0" e2="DDI-PubMed.17535786.s9.e2" /><pair ddi="false" e1="DDI-PubMed.17535786.s9.e1" e2="DDI-PubMed.17535786.s9.e1" /><pair ddi="false" e1="DDI-PubMed.17535786.s9.e1" e2="DDI-PubMed.17535786.s9.e2" /></sentence><sentence text=" 7 contraindications and 15 unadvised associations were held" /><sentence text=" For 58% of interactions, no management recommendation was specified in the bibliographic source" /><sentence text=" Healthcare professionals must be aware that the Vidal dictionary gave information for only 26 % of registered drug-drug interactions" /><sentence text=" Our database gather in one document drug-drug interactions that come from different bibliographic sources" /><sentence text=" The setting of this database is part of the multidisciplinary caring of cancer patient" /><sentence text=" Drug-drug interaction is a field which for physicians and pharmacists should developed collaboration for patient care" /><sentence text="" /></document>